Publications by authors named "F Pataky"
SOX10 belongs to the family of transcription factors essential for the development of neural crest, peripheral nervous system and melanocytes. It is presently used in histopathology as a marker of melanocytic differentiation. SOX10 is expressed in normal brain tissue in oligodendrocytes, but the information about SOX10 expression in primary tumors of the central nervous system is quite limited.
View Article and Find Full Text PDFUnlabelled: Gliosarcoma (GS) is a relatively rare glioblastoma variant characterized by biphasic glial and mesenchymal differentiation patterns. The sarcomatous part most commonly resembles fibrosarcoma or so-called malignant fibrous histiocytoma. Rarely, GS shows heterologous lines of differentiation in the form of osteosarcoma, chondrosarcoma, liposarcoma, leiomyosarcoma, squamous or glandular malignant epithelial differentiation, or primitive neuroectodermal tumor (PNET)-like foci.
View Article and Find Full Text PDFClassification, grading and treatment of central nervous system tumors is currently based on morphology. Advances in molecular biology help to clarify pathogenesis, refine prognosis and detect potential targets for targeted therapy in a wide spectrum of CNS tumors. In this short review we present our view on selected diagnostic, prognostic and predictive biomarkers of primary CNS tumors, with an emphasis on application in daily praxis.
View Article and Find Full Text PDFArticle Synopsis
- Medication discrepancies can occur during hospital admission, transfer, or discharge, especially due to therapeutic interchange practices that substitute requested medications with those on the hospital's formulary.
- The study aimed to assess how differences in proton pump inhibitor (PPI) formularies between St Paul's Hospital and the British Columbia PharmaCare program affected medication discrepancies at discharge.
- Results indicated that discharge discrepancy rates increased from 27.3% to 49.1% when the hospital and provincial formularies for PPIs were misaligned, highlighting the significant impact of formulary differences on patient safety.
Introduction: One of possibility of treatment FBSS is posterior lumbar interbody fusion, PLIF with posterior transpedicular stabilization.
Material And Methods: Between January 2005 and December 2007, the prospective study of treatment failed back surgery syndrome patients with posterior lumbal interbody fusion and posterior transpedicular stabilization was performed at the Department of Neurosurgery University Hospital FNLP in Kosice. Physical examinations were performed before surgery, after surgery 30 days, and at 4 follow-up visits (3 months, 6 months, 12 months and 24 months).